What happened in optometry this week: May 27 - May 31
Catch up on what happened in optometry during the week of May 27-May 31.
Catch up with what Optometry Times shared this week:
Second person in US infected with H5N1 bird flu, main symptom is conjunctivitis
By Lynda Charters
There is a current outbreak of H5N1 globally in poultry and other animals. H5N1 is a very contagious strain of avian influenza A that, thus far, has been confirmed in 9 states in dairy cows and in 2 individuals. The government of Australia reported infection in a child with a different strain than the current one in the US on Tuesday, May 21.
According to the CDC, there has been no human-to-human spread associated with the 2 cases.
Dopavision announces topline results for MyopiaX trial for slowing pedatric myopia progression
By Jordana Joy, Associate Editor
Dopavision has announced topline findings from its MyopiaX-1 proof-of-concept clinical trial investigating the safety and tolerability of MyopiaX, which delivers targeted photobiomodulation to the eye for managing the progression of pediatric myopia, according to a news release. Data from the trial found that MyopiaX proved clinically safe and tolerable, in addition to showing clinical effect on the rate of myopia progression.1
Visual field testing undergoes modern transformation via wearable technology
By Jason Bacharach, MD
For the past 3 decades, visual field testing has remained relatively stagnant, with the bowl perimeter occupying a central role in the examination rooms of eye care providers worldwide. Despite advancements in various fields, this cornerstone technology has seen little innovation. However, recent breakthroughs in microdisplays, battery longevity, and wearable devices have sparked a revolution in visual diagnostics. Among these is Radius XR, which offers a wearable, mobile headset and a diagnostic platform that combines accuracy, efficiency, portability, and patient comfort.
Opthea completes enrollment for sozinibercept (OPT-302) trials in pivotal Phase 3 program
By Jordana Joy, Associate Editor
Clinical stage biopharmaceutical company Opthea Limited has announced enrollment completion for the COAST and ShORe trials in the pivotal Phase 3 program for treatment of patients with wet age-related macular degeneration (AMD).1 The announcement follows the enrollment completion of the COAST trial from earlier this year.2
“Today marks the achievement of a key milestone for the sozinibercept global Phase 3 clinical trial program that brings us closer to our goal of improving visual outcomes for patients with wet AMD,” said Arshad M Khanani, MD, MA, FASRS, chief medical advisor of Opthea, in a news release.
ARVO 2024: Understanding the pharmacokinetics of latanoprost and prednisolone acetate with perfluorohexyloctane
By Megan Cavet, PhD, and Emily Kaiser Maharjan, Assistant Managing Editor
Megan Cavet, PhD, sat down with Emily Kaiser Maharjan of Optometry Times to discuss her 2024 ARVO poster, "Effects of perfluorohexyloctane on the ocular pharmacokinetics of latanoprost and prednisolone acetate after topical administration to rabbits." The study investigated the effects of the long-lasting monolayer created by perfluorohexyloctane and whether the order of administration affected the absorption of active ingredients.
